



Published in final edited form as:

Biochem Biophys Res Commun. 2015 January 2; 456(1): 190–196. doi:10.1016/j.bbrc.2014.11.057.

Protein tyrosine kinase 6 mediates TNF α -induced endothelial barrier dysfunction

RJ Haines¹, RS Beard², and MH Wu¹

¹Department of Surgery, University of South Florida, Morsani College of Medicine

²Department of Molecular Pharmacology and Physiology, University of South Florida, Morsani College of Medicine

Abstract

A key event in the progression of systemic inflammation resulting from severe trauma or shock involves microvascular hyperpermeability, which leads to excessive plasma fluid and proteins accumulating in extravascular space resulting in tissue edema. The precise molecular mechanism of the hyperpermeability response is not completely understood. Protein tyrosine kinase 6 (PTK6, also known as breast tumor kinase BRK) is a non-receptor tyrosine kinase related to Src-family proteins. Although it has also been shown that PTK6 participates in regulating epithelial barrier function, the role of PTK6 in endothelial barrier function has not been reported. In this study, we hypothesized that PTK6 is 1) expressed in vascular endothelial cells, and 2) contributes to vascular endothelial hyperpermeability in response to TNF α . Results showed that PTK6 was detected in mouse endothelial cells at the level of protein and mRNA. In addition, PTK6 knockdown attenuated TNF α induced decrease in endothelial barrier function as measured by electric cell-substrate impedance sensing (ECIS) and *in vitro* transwell albumin-flux assays. Furthermore, we showed that TNF α treatment of endothelial cells increased active PTK6 association with p120-catenin at endothelial cell-cell junctions. Further analysis using immunocytochemistry and immunoprecipitation demonstrated that PTK6 knockdown attenuated TNF α induced VE-cadherin internalization as well as promoting its association with p120-catenin. Our study demonstrates a novel role of PTK6 in mediating endothelial barrier dysfunction.

Keywords

Endothelial barrier function; p120-catenin; VE-cadherin; PTK6

© 2014 Elsevier Inc. All rights reserved.

Corresponding Author: Dr. Mack Wu, Professor of Surgery and Molecular Medicine, University of South Florida, Morsani College of Medicine, 12901 Bruce B. Downs Blvd., MDC 8. Office MDC 2013A, Tampa, FL 33612, Phone: (813) 974-6953, mwu1@health.usf.edu.

Disclosures: None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Exchange microvessels are composed of endothelium that forms an effective barrier to control movement of blood fluid and proteins across the vessel wall. Disruption of the endothelial barrier leads to microvascular leakage and tissue edema resulting in organ dysfunction.[1,2] This pathological process is involved in many diseases such as sepsis, ischemia-reperfusion, and systemic inflammation due to traumatic injuries. [3,4] In particular, intestinal microvascular hyperpermeability resulting from severe trauma or burn contributes to intestinal hypoxia and tissue damage leading to breach of the intestinal mucosa and sepsis [5] as well as abdominal compartmental syndrome. Therefore, one of the clinical strategies in treating severe trauma is to restore endothelial barrier function of the microvasculature and prevent further tissue damage caused by edema. [3]

Systemic inflammation activates leukocytes in a manner that causes the release of inflammatory mediators including histamine, tumor necrosis factor alpha (TNF α), and interleukins. These mediators trigger intracellular signaling events of the microvascular endothelium leading to changes of endothelial structure proteins which give rise to endothelial hyperpermeability. [6,7] TNF α is a cytokine released from activated leukocytes involved in mediating systemic inflammatory response syndrome (SIRS).[8] In fact, intravenous injection of TNF α induces SIRS in rats. [9] In endothelial cells, TNF α induces hyperpermeability in part by tyrosine phosphorylation of VE-cadherin (Y658) followed by its internalization and degradation. [10,11] Tyrosine phosphorylation of VE-cadherin interrupts its association with p120-catenin, an association that is barrier protective in that p120-catenin promotes VE-cadherin retention at the plasma membrane. [12] It has been established that TNF α induces activation of the Src-family kinase Fyn which targets VE-cadherin and mediates its internalization in human lung endothelia.[10] Interestingly, the non-receptor tyrosine kinase evolutionarily related to Src-family kinases, protein tyrosine kinase 6 (PTK6),[13] activation and translocation to the plasma membrane was shown to be inversely related with E-cadherin downregulation in epithelial cells.[14] Furthermore, several key components of the cell-cell junction and cell-matrix adhesions are directly phosphorylated by PTK6, including paxillin [15], β -catenin [16], and focal adhesion kinase [17]. However the role of PTK6 in mediating VE-cadherin expression or internalization in endothelial cells has not been explored.

It is well known that the non-receptor protein tyrosine kinase Src and several Src-related kinases (Fyn, Yes, Lck, Lyn, Hck, Fgr, Blk) are involved in mediating vascular permeability in response to inflammation [18]. Although distinct from Src-family kinases, the intestinal kinase PTK6 is a nonreceptor tyrosine kinase evolutionarily related to Src-family kinases. PTK6 shares common motifs with Src including SH2 and SH3 (Src-homology) domains [19,20], and is regulated in a similar manner in that a C-terminal tyrosine residue (Y447) negatively regulates its kinase activity by binding to the SH2 domain when phosphorylated [21]. In addition, PTK6 autophosphorylates residue Y342 which activates the kinase.[13] Although few studies have addressed the pathogenic role of PTK6 in a nononcogenic context, Whitehead et al showed that PTK6 $^{-/-}$ mice demonstrate robust colonic epithelial barrier function relative to their wild-type counterparts [22]. Considering that the PTK6 structure is similar to Src-family kinases and is involved in epithelial barrier function, we

hypothesized that PTK6 is expressed in endothelial cells and may play a role in TNF α -mediated endothelial barrier dysfunction.

Methods

Cell culture and treatment

Primary mouse intestinal endothelial cells isolated from small intestine vasculature (Cell Biologics) were grown to confluence as described by vendor in endothelial medium supplemented with 10% FBS. For experiments, *cells between passage 3 and 6* were grown to 2-3 days post-confluence then were treated with vehicle control (0.1% BSA in PBS) or TNF α (Sigma, 60 ng/ml) for indicated time-points after serum starvation for 18 hours. Cells were lysed with assay specific lysis buffer followed by RNA extraction and quantification or BCA protein assay (Pierce) for protein determination prior to qPCR, Western blotting, immunoprecipitation, and cellular fractionation experiments.

Quantitative PCR

Treated endothelial cells were lysed in RNazol (Molecular Research Center, Inc) followed by RNA extraction as described by manufacturer. The mRNA fraction was quantified and equal masses of RNA were reverse transcribed to cDNA using random hexamers prior to qPCR. Equal volumes of cDNA were used to quantify PTK6 message using specific primers (sequence of primers is proprietary, Bio-Rad) and SYBR master mix (Bio-Rad) according to manufacturer's instructions. Samples were assayed in triplicate followed by analysis comparing relative expression levels using GAPDH as the housekeeping gene via CFX96 Touch Real-Time PCR detection system and software (Bio-Rad).

Nuclear fractionation

Endothelial cells were lysed in fractionation buffer (250 mM sucrose, 20 mM HEPES pH 7.4, 1.5 mM MgCl₂, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1X phosphatase inhibitor cocktail (Pierce)) followed by several passages through 25 G needle. After nuclear extraction (3,000 RPM, 4°C, 5 minutes), the membrane pellet was harvested by ultracentrifugation (40,000 RPM, 4°C, 1 hour) with the supernatant retained as the cytosolic fraction. The fractions were subjected to BCA protein assay (Pierce) prior to Western blot analysis to assess changes in protein localization relative to treatment. Equal masses of protein were loaded to 4-20% polyacrylamide gels (Bio-Rad) for SDS-PAGE followed by Western blotting using PTK6 antibody (Santa Cruz), or Caveolin-1 antibody (BD biosciences) to determine membrane isolation efficiency.

Electric cell-substrate impedance sensing (ECIS)

ECIS was performed as described previously. [23] Briefly, endothelial cells were transfected with siRNA (IDT) directed against PTK6 or vehicle control (TE) via electroporation in electroporation solution (Mirus) using a Bio-Rad Gene Pulser Xcell according to manufacturer's instructions. Cells were then plated on fibronectin coated, gold plated ECIS chamber slides (Applied Biophysics, 8W10E+) at 5 X 10⁵ cells/ml and allowed to express siRNA for 72 hours followed by treatment with vehicle control (0.1% BSA in PBS) or TNF α (30 ng/ml) for indicated time-points. Resistance measurements taken from the

endothelial monolayers were recorded every 90 seconds and normalized to time-point zero. After ECIS measurements were complete, cells were lysed in RNAzol and PTK6 was assayed by qPCR to confirm knockdown.

Monolayer albumin-flux assay

Albumin-flux assays were conducted as previously described. [24] Endothelial cells were transfected with siRNA directed against PTK6 or vehicle control (TE) as described above. Cells were plated on fibronectin coated polycarbonate 24-well transwell inserts (0.4 μ M pore size, Corning) and allowed to express siRNA for 72 hours followed by treatment with vehicle control (0.1% BSA in PBS) or TNF α (30 ng/ml) for indicated time-points. Following treatment, the luminal (top) compartment was treated with FITC-labeled albumin (2.5 mg/ml) for 45 minutes, then 100 μ l aliquots were obtained from each abluminal (bottom) compartment and assayed for FITC fluorescence. Permeability coefficients were calculated using the formula $P_a = [Ab] / t \times 1/A \times V/[Lu]$, where [Ab] is the abluminal concentration of FITC-albumin, t is time in seconds for FITC-albumin incubation, A is area of membrane in cm², V is the volume of the abluminal chamber, and [Lu] is the luminal concentration of FITC-albumin.

Immunoprecipitation

Endothelial cells were grown to confluence then electroporated with siRNA directed against PTK6 or vehicle control (TE) as described above. Once cells reached 2-3 days post-confluence, cells were serum starved overnight then treated with TNF α or vehicle control (0.1% BSA in PBS) for 6 hours. Cells were lysed with immunoprecipitation buffer followed by pre-clearing with agarose beads. Antibodies directed against proteins of interest were conjugated to agarose beads then added to pre-cleared lysates (500 μ g protein) and allowed to incubate with rotisserie motion at 4°C overnight. Beads were harvested by centrifugation and washed with PBS 5 times followed by target elution with elution buffer. Co-immunoprecipitation was assessed by SDS-PAGE of eluted proteins followed by Western blotting for proteins of interest.

VE-cadherin internalization assay

Experiment was conducted as described by Malik et al with modifications.[11] Briefly, mock or PTK6 siRNA electroporated cells were grown to confluence on fibronectin coated slides followed by serum starvation in 3% BSA containing media. Cells were allowed to incubate with antibody directed against VE-cadherin extracellular domain at 4°C for 1 hour, followed by treatment with either TNF α or vehicle control at 37°C overnight in media containing 3% BSA and 100 μ M chloroquine (prevents intracellular degradation of VE-cadherin). In order to enhance visualization of intracellular VE-cadherin, extracellular VE-cadherin was removed by washing cells in low pH buffer (PBS pH 2.7). Cells were then fixed with ice cold methanol then permeabilized with 0.3% triton X followed by blocking in 0.5% BSA in PBS. Incubation with antibody against p120-catenin (Santa Cruz) was conducted to determine co-localization with VE-cadherin relative to treatment. Detection of primary antibodies was performed by incubating cells with goat anti-mouse alexafluor 488 for VE-cadherin and goat anti-rabbit alexafluor 568 (Life Technologies) for p120-catenin for 1 hour. ProLong Gold Anti-fade with DAPI (Life Technologies) was used to stain nuclei and

mount coverslips. Images were acquired using the Olympus FV1000 MPE Multiphoton Laser Scanning Microscope.

Statistics

One-way ANOVA was used to identify significant difference among groups ($p < 0.05$). The Student's *t*-test was used to determine significant difference ($p < 0.05$) between indicated groups noted by (*) or (¥).

Results

PTK6 is expressed in endothelial cells

Considering the significance of PTK6 in basal epithelial barrier function,[22] we first sought to determine whether PTK6 is expressed in endothelial cells. Primary microvascular endothelial cells were treated with siRNA directed against PTK6 then assayed for expression at the level of mRNA and protein. As shown in Figure 1A-B, cells treated with siRNA against PTK6 showed diminished PTK6 expression at the level of mRNA and protein when compared to mock transfected controls. Furthermore, confocal microscopy showed that PTK6 was detected in the perinuclear and cytosolic regions of untreated endothelial cells (Figure 1C).

PTK6 knockdown rescued TNF α mediated endothelial barrier dysfunction

Next, we hypothesized that PTK6 plays a role in TNF α induced endothelial barrier dysfunction. *We tested this by assessing barrier function in two ways. First*, we transfected endothelial cells with siRNA directed against PTK6 or mock transfected cells then plated on ECIS arrays and recorded resistance measurements of cells treated with TNF α or vehicle control. As shown in Figure 2A-B, PTK6 knockdown significantly attenuated TNF α mediated barrier dysfunction by approximately 75%. *Next, we utilized* endothelial albumin-flux assays which showed that PTK6 knockdown significantly attenuated TNF α induced endothelial albumin-flux by approximately 50% of TNF α treated mock transfected controls (Figure 2C).

TNF α induced PTK6 translocation to the plasma membrane and cell-cell junctions

In order to determine localization changes of PTK6 with respect to treatment, we treated endothelial cells with increasing doses of TNF α and harvested the membrane fraction using sucrose fractionation. As shown in Figure 3A, PTK6 detection in the plasma membrane fraction was positively correlated with increased doses of TNF α . Next, since PTK6 contains SH2 and SH3 domains that may allow it to associate with the adherens junction protein p120-catenin,[13] an important endothelial membrane scaffolding protein involved in maintaining VE-cadherin stability, we hypothesized that PTK6 associated with p120-catenin. Cells were treated with TNF α or vehicle control then p120-catenin was immunoprecipitated. Proteins co-eluted with p120-catenin were probed for presence of PTK6. As demonstrated in Figure 3B, TNF α induced PTK6 association with p120-catenin in endothelial cells. To further analyze TNF α induced PTK6 association with p120-catenin, we utilized immunocytochemistry to examine any co-localization events between active PTK6

(pY342 PTK6) and p120-catenin upon TNF α treatment. As indicated in Figure 3C, TNF α promoted p120-catenin targeting of pY342 PTK6 at cell-cell junctions.

PTK6 inhibition improved VE-cadherin stabilization in presence of TNF α

Since the Src-family kinase Fyn is known to phosphorylate VE-cadherin at Y658 and mediate its internalization in response to TNF α , [10] and PTK6 has common protein domains with Fyn, we hypothesized that PTK6 may be involved in VE-cadherin phosphorylation upon TNF α stimulation. Results showed that PTK6 knockdown prevented TNF α induced phosphorylation of VE-cadherin at Y658 (Figure 4A). Next, immunocytochemistry showed that PTK6 knockdown deterred VE-cadherin internalization resulting from TNF α treatment (Figure 4B). Since it has been established that Y658 phosphorylation interferes with VE-cadherin association with p120-catenin,[25] and this interference allows internalization of cadherins [26,27] to promote endothelial permeability, we sought to determine whether PTK6 inhibition with siRNA restored p120-catenin association with VE-cadherin with TNF α treatment. As indicated in Figure 4C, VE-cadherin detection was improved when p120-catenin was immunoprecipitated from TNF α treated cells expressing PTK6 siRNA relative to TNF α treated mock transfected cells, suggesting that PTK6 may function in modulating p120-catenin association with VE-cadherin.

Discussion

Considering that the kinase PTK6 plays a role in epithelial barrier function, we sought to determine whether PTK6 modulates TNF α induced endothelial hyperpermeability. After first identifying the presence of PTK6 in endothelial cells at the level of protein and mRNA, we then explored the functional role of PTK6 in the context of inflammation by stimulating endothelial cells with TNF α . Results showed that decreasing PTK6 expression attenuated TNF α induced barrier dysfunction and albumin-flux, suggesting that PTK6 indeed contributes to impaired barrier function resulting from TNF α . *In addition, we found that PTK6 protein expression was elevated in lung tissue harvested from mice that underwent cecal ligation and puncture (CLP) to mimic sepsis (data not shown), suggesting PTK6 may play a role in mediating inflammation in vivo.* We then assessed the spatial regulation of PTK6 and found that PTK6 translocated to the endothelial cell-cell junctions and immunoprecipitated with the junction scaffolding protein, p120-catenin, upon stimulation with TNF α , further strengthening the idea that PTK6 plays a role in regulating endothelial junction dynamics. We further demonstrated that PTK6 is involved in adherens junction regulation by showing PTK6 co-eluted with p120-catenin in lysates of TNF α treated cells, but not untreated cells, suggesting that TNF α promotes p120-catenin PTK6 co-localization.

Src-related kinases are activated by inflammatory cytokines including TNF α . [28] *Our previous study first linked activated neutrophil-mediated changes in VE-cadherin tyrosine phosphorylation, internalization and barrier dysfunction in cultured microvascular endothelial cells.* [29] *Others reported VE cadherin internalization as a key step in disrupting endothelial barrier function by Src-dependent mechanisms in response to VEGF.* [30,31]. *Most recently, Dejana's group has demonstrated that Src activation in veins resulted in increased VE-cadherin phosphorylation at Y658 and subsequent internalization*

in vivo. Inhibiting this phosphorylation event prevented VE-cadherin internalization and improved vascular leakage induced by inflammatory mediators such as bradykinin or histamine. [32] Tyrosine phosphorylation of VE-cadherin leads to internalization and degradation of VE-cadherin, followed by increased intercellular gap formation thus contributing to permeability to plasma proteins and leukocytes.[29,32] In our study, we showed that TNF α induced cell-junction localization of endothelial PTK6, a Src-related kinase, indicating that TNF α places PTK6 in the vicinity of cell-cell junctions and therefore may also target junction proteins as do other Src-family kinases. Since TNF α is known to induce tyrosine phosphorylation (VE-cadherin pY658) and subsequent interference of the barrier protective p120-catenin:VE-cadherin association,[25] we hypothesized that a possible mechanism for PTK6 induced increase in endothelial permeability may involve VE-cadherin. Indeed, we showed that PTK6 knockdown diminished pY658 phosphorylation of VE-cadherin induced by TNF α . The next logical question was to determine whether PTK6 knockdown prevented TNF α induced VE-cadherin internalization. Consistent with aforementioned experiments, immunodetection of internalized VE-cadherin was attenuated in TNF α treated cells transfected with PTK6 siRNA, suggesting that PTK6 plays a role in the internalization of VE-cadherin. Since VE-cadherin tyrosine phosphorylation and internalization is alleviated when associated with p120-catenin, [25,33] showing that knocking down PTK6 in TNF α treated cells increased p120-catenin association with VE-cadherin when compared to mock transfected TNF α treated cells suggested that PTK6 may be associated with regulating p120-catenin interaction with VE-cadherin in a manner that promotes VE-cadherin internalization. Taken together, these results demonstrate a previously unrecognized role for PTK6 as a novel signaling molecule in mechanisms underlying endothelial barrier dysfunction resulting from inflammation.

Acknowledgments

Sources of Funding: National Institutes of Health HL096640 and HL120954.

References

1. Yuan, SYSY.; Rigor, RRRR. Regulation of Endothelial Barrier Function. Morgan & Claypool Life Sciences; San Rafael (CA): 2010.
2. Mehta D, Malik AB. Signaling Mechanisms Regulating Endothelial Permeability. *Physiological Reviews*. 2006; 86:279–367. [PubMed: 16371600]
3. Demling RH. The burn edema process: current concepts. *J Burn Care Rehabil*. 2005; 26:207–227. [PubMed: 15879742]
4. Sun C, Wu MH, Yuan SY. Nonmuscle Myosin Light-Chain Kinase Deficiency Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice via Reduced Endothelial Barrier Dysfunction and Monocyte MigrationClinical Perspective. *Circulation*. 2011; 124:48–57. [PubMed: 21670231]
5. Tadros T, Traber DL, Heggors LP, Herndon DN. Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis. *Ann Surg*. 2003; 237:101–109. [PubMed: 12496536]
6. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. *Expert Reviews in Molecular Medicine*. 2009; 11
7. Beard RS, Haines RJ, Wu KY, Reynolds JJ, Davis SM, Elliott JE, Malinin NL, Chatterjee V, Cha BJ, Wu MH, Yuan SY. Non-muscle Myosin is required for beta-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1 beta-mediated barrier dysfunction in brain endothelial cells. *Journal of Cell Science*. 2014; 127:1840–1853. [PubMed: 24522189]

8. Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. *Injury*. 2007; 38:1336–1345. [PubMed: 18048040]
9. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3rd, Zentella A, Albert JD, et al. Shock and tissue injury induced by recombinant human cachectin. *Science*. 1986; 234:470–474. [PubMed: 3764421]
10. Angelini DJ, Hyun SW, Grigoryev DN, Garg P, Gong P, Singh IS, Passaniti A, Hasday JD, Goldblum SE. TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia. *Am J Physiol Lung Cell Mol Physiol*. 2006; 291:L1232–1245. [PubMed: 16891393]
11. Gong H, Gao X, Feng S, Siddiqui MR, Garcia A, Bonini MG, Komarova Y, Vogel SM, Mehta D, Malik AB. Evidence of a common mechanism of disassembly of adherens junctions through Galphal3 taring of VE-cadherin. *J Exp Med*. 2014; 211:579–591. [PubMed: 24590762]
12. Xiao K, Garner J, Buckley KM, Vincent PA, Chiasson CM, Dejana E, Faundez V, Kowalczyk AP. p120-Catenin Regulates Clathrin-dependent Endocytosis of VE-Cadherin. *Molecular Biology of the Cell*. 2005; 16:5141–5151. [PubMed: 16120645]
13. Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6—BRK by BRK. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*. 2010; 1806:66–73.
14. Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, Macias V, Kajdacsy-Balla A, Tyner AL. PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. *Cancer Res*. 2013; 73:5426–5437. [PubMed: 23856248]
15. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates racl and promotes cell migration and invasion by phosphorylating paxillin. *Mol Cell Biol*. 2004; 24:10558–10572. [PubMed: 15572663]
16. Palka-Hamblin HL, Gierut JJ, Bie W, Brauer PM, Zheng Y, Asara JM, Tyner AL. Identification of β -catenin as a target of the intracellular tyrosine kinase PTK6. *Journal of Cell Science*. 2010; 123:236–245. [PubMed: 20026641]
17. Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. *Oncogene*. 2013; 32:4304–4312. [PubMed: 23027128]
18. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. *Cell Tissue Res*. 2009; 335:249–259. [PubMed: 18815812]
19. Hong E, Shin J, Bang E, Kim MH, Lee ST, Lee W. Complete sequence-specific 1H, 13C and 15N resonance assignments of the human PTK6 SH2 domain. *J Biomol NMR*. 2001; 19:291–292. [PubMed: 11330822]
20. Kim H, Jung J, Lee ES, Kim YC, Lee W, Lee ST. Molecular dissection of the interaction between the SH3 domain and the SH2-Kinase Linker region in PTK6. *Biochem Biophys Res Commun*. 2007; 362:829–834. [PubMed: 17822667]
21. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. *J Biol Chem*. 2002; 277:34634–34641. [PubMed: 12121988]
22. Whitehead RH, Robinson PS, Williams JA, Bie W, Tyner AL, Franklin JL. Conditionally immortalized colonic epithelial cell line from a Ptk6 null mouse that polarizes and differentiates in vitro. *J Gastroenterol Hepatol*. 2008; 23:1119–1124. [PubMed: 18205771]
23. Tiruppathi C, Malik AB, Del Vecchio PJ, Keese CR, Giaever I. Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function. *Proc Natl Acad Sci U S A*. 1992; 89:7919–7923. [PubMed: 1518814]
24. Sun C, Wu MH, Guo M, Day ML, Lee ES, Yuan SY. ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. *Cardiovascular Research*. 2010; 87:348–355. [PubMed: 20189953]
25. Potter MD, Barbero S, Cheresch DA. Tyrosine Phosphorylation of VE-cadherin Prevents Binding of p120- and β -Catenin and Maintains the Cellular Mesenchymal State. *Journal of Biological Chemistry*. 2005; 280:31906–31912. [PubMed: 16027153]

26. Hatanaka K, Simons M, Murakami M. Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. *Am J Physiol Heart Circ Physiol.* 2011; 300:H162–172. [PubMed: 21037229]
27. Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. *J Cell Biol.* 2003; 163:525–534. [PubMed: 14610055]
28. Okutani D, Lodyga M, Han B, Liu M. Src protein tyrosine kinase family and acute inflammatory responses. *Am J Physiol Lung Cell Mol Physiol.* 2006; 291:L129–141. [PubMed: 16581827]
29. Tinsley JH, Wu MH, Ma W, Taulman AC, Yuan SY. Activated Neutrophils Induce Hyperpermeability and Phosphorylation of Adherens Junction Proteins in Coronary Venular Endothelial Cells. *Journal of Biological Chemistry.* 1999; 274:24930–24934. [PubMed: 10455168]
30. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. *Nat Cell Biol.* 2006; 8:1223–1234. [PubMed: 17060906]
31. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. *J Cell Biol.* 2004; 167:223–229. [PubMed: 15504909]
32. Orsenigo F, Giampietro C, Ferrari A, Corada M, Galaup A, Sigismund S, Ristagno G, Maddaluno L, Koh GY, Franco D, Kurtcuoglu V, Poulikakos D, Baluk P, McDonald D, Grazia Lampugnani M, Dejana E. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. *Nat Commun.* 2012; 3:1208. [PubMed: 23169049]
33. Yuan, SY.; Rigor, RR. *Regulation of Endothelial Barrier Function.* San Rafael (CA): 2010.

Abbreviations

PTK6	protein tyrosine kinase 6
TNFα	tumor necrosis factor α
ECIS	electric cell-substrate impedance sensing
siRNA	silencing ribonucleic acid
E-cadherin	epithelial cadherin
VE-cadherin	vascular endothelial cadherin
mRNA	messenger ribonucleic acid

Highlights

- Endothelial hyperpermeability resulting from inflammation can lead to death.
- The role of PTK6 in endothelial permeability has not been determined.
- Inhibition of PTK6 improved inflammation mediated endothelial hyperpermeability.
- Inflammation induced endothelial activation and membrane localization of PTK6.
- PTK6 may be a novel target for improving endothelial hyperpermeability.




Figure 1.

PTK6 is expressed in endothelial cells. **A-B**, Endothelial cells were either mock transfected or transfected with PTK6 siRNA and allowed to express siRNA for 48 hours. Cells were lysed followed by protein and mRNA extraction then analyzed by Western blot **A**, and qPCR **B**. **C**, Endothelial cells were probed with antibodies against p120-catenin and PTK6 antibody then detected with Alexafluor secondary antibodies (p120-catenin 568nm (red), PTK6 488nm (green)) and confocal microscopy. Results are representative of 3 experiments. * $p < 0.05$.






Figure 2.

PTK6 knockdown rescued TNF α mediated decrease in transendothelial electrical resistance (TER) and *attenuated TNF α induced albumin flux*. **A**, Endothelial cells were either mock transfected or transfected with PTK6 siRNA then seeded on ECIS electrodes and treated with 60 ng/ml TNF α . TER values were measured and normalized to time-point zero. **B**, Quantitative analysis of TER values at timepoints 0 and 10 hours. Results are representative of 4 experiments. * $p < 0.05$ (Mock + TNF) and (PTK6 siRNA + TNF) vs. control, ¥ $p < 0.05$ (Mock + TNF) vs. (PTK6 siRNA + TNF) **C**, Endothelial cells were either mock transfected or transfected with siRNA directed against PTK6 then seeded on 0.4 μ M transwell inserts then treated with TNF α (60ng/ml) for 15 hours. FITC-labeled albumin (0.25mg/ml) was loaded to the apical chamber for 45 minutes then abluminal chamber was analyzed for presence of fluorescence. Results are representative of 4 experiments. * $p < 0.05$ (Mock + TNF) and (PTK6 siRNA + TNF) vs. control, ¥ $p < 0.05$ (PTK6 siRNA + TNF) vs. (Mock + TNF)

**Figure 3.**

TNF α induced PTK6 translocation to the plasma membrane and cell-cell junctions. Endothelial cells were treated with vehicle control (VC) or TNF α (60ng/ml unless otherwise stated) for 3 hours. **A**, Cells were subjected to subcellular fractionation via sucrose gradient centrifugation followed by Western blot to determine PTK6 localization. Caveolin-1 was probed to confirm enrichment of membrane proteins. **B**, p120-catenin was immunoprecipitated then PTK6 was detected in co-eluted proteins. p120-catenin immunodetection was assayed to ensure equal loading. **C**, Confocal microscopy showed

enhanced cell-cell junction localization of active PTK6 (pY342) upon TNF α treatment. Cell junctions are indicated by enhanced detection of p120-catenin. Arrows indicate areas of cytosolic pY342 PTK6 (left) vs. cell-junction localized pY342 PTK6 (right). Results are representative of 3 experiments.

**Figure 4.**

PTK6 inhibition improved VE-cadherin stabilization in presence of TNF α . endothelial cells were either mock transfected or transfected with siRNA directed against PTK6 then treated with vehicle control (VC) or TNF α (60ng/ml) for 3 hours. **A**, Whole cell lysates were analyzed by Western for VE-cadherin Y658 phosphorylation and total expression. β -actin was probed as loading control. **B**, Internalized VE-cadherin was immunodetected using antibodies directed against the external region of the molecule. Non-internalized VE-cadherin was removed with a low pH wash. Arrows indicate areas of impaired VE-cadherin detection (first and last vertical panels) or enhanced VE-cadherin detection (middle panel). p120-catenin was probed to identify cell junctions for orientation. **C**, VE-cadherin immunodetection was assayed in co-eluted proteins from equal masses of protein cell lysates immunoprecipitated with p120-catenin antibody. Total PTK6, VE-cadherin and β -actin were assayed to indicate efficient knockdown and equal loading, respectively. All results are representative of 3 experiments.